We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cytokinetics’ omecamtiv mecarbil received an 8-3 thumbs-down from the FDA’s Cardiovascular and Renal Drugs Advisory Committee, with the majority agreeing that the risks of the myosin activator outweigh its benefits for treating patients with heart failure and reduced ejection fraction. Read More
The landmark Inflation Reduction Act (IRA) passed in August means good news for seniors who need insulin, but diabetics under age 65 are still waiting for relief as legislators, regulators and industry all work toward lowering the price of the life-sustaining drug. Read More
In the biggest pharmaceutical purchase announced this year, Amgen has inked a $28 billion deal with Horizon Therapeutics, gaining access to one blockbuster eye drug and two others that are future revenue-drivers. Read More
For the Moderna option, children between six months and five years old can receive a single bivalent booster dose two months after completing the primary series. Read More